Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIRACAN phase 2 trial of atezolizumab + tiragolumab in solid tumors
NL-OMON58672Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab and tiragolumab in head and neck squamous cell carcinoma (HNSCC), microsatellite instability-high cancer, mismatch repair deficient solid tumor and 2 more (4 arms), sponsored by University Medical Center Groningen. Primary endpoints: Pathologic response rate and Objective response rate. Started Oct 2023; status: active, not recruiting.
02
Drugs
atezolizumabtiragolumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)microsatellite instability-high cancermismatch repair deficient solid tumormelanomaNonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON58672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58672.